Term ends Nov 24, 2030 · Medium confidence
20-year base term ends Nov 24, 2030
Why Medium: A parent in the chain could not be resolved.
Held by MedImmune Limited
Filed Oct 25, 2016 as application 15/333,683 · Granted Sep 3, 2019
Base term plus 125 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
2010
2030
Clock starts
Nov 24, 2010
Nov 24, 2010
Term ends
Nov 24, 2030
Nov 24, 2030
Granted
Sep 3, 2019
Sep 3, 2019
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
125
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 8,779,108.
1 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
6
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 125 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 1 of 2 maintenance fees is paid so far. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 24, 2010, when application PCT/US2010/058007, the earliest non-provisional in its chain, was filed (this one was filed Oct 25, 2016); a parent in its chain could not be resolved (the next row) | Nov 24, 2030 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +125 days, USPTO patent term adjustment record | Mar 29, 2031 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,779,108) | capped to Nov 24, 2030 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Nov 24, 2030 | Medium confidence |
This family
| US 8,779,108 | In force Nov 2030 | Nov 2030 |
| US 9,493,565 | In force May 2031 | May 2031 |
| US 10,400,039 | this patent Nov 2030 | Nov 2030 |
| US 11,518,809 | In force Nov 2030 | Nov 2030 |
| US 12,686,718 | In force Jun 2031 | Jun 2031 |
5 of 6 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Aug 17, 2018 Reel 46857, frame 675 | Hammond, Scott; Mulgrew, Kathleen Ann | MedImmune, LLC | Assignment of Assignor's Interest |
| Aug 17, 2018 Reel 46858, frame 214 | Queva, Christophe; Babcook, John; Foltz, Ian Nevin; Kang, Jaspal Singh; Sekirov, Laura | Amgen British Columbia | Assignment of Assignor's Interest |
| Aug 17, 2018 Reel 46859, frame 277 | Morrow, Michelle; Boyle, Melanie; Chodorge, Matthieu; Stewart, Ross A. | MedImmune Limited | Assignment of Assignor's Interest |
| Aug 17, 2018 Reel 46859, frame 430 | Alimzhanov, Marat | AstraZeneca AB | Assignment of Assignor's Interest |
| Aug 17, 2018 Reel 46859, frame 675 | Amgen British Columbia | MedImmune Limited | Assignment of Assignor's Interest |
| Aug 23, 2018 Reel 46676, frame 236 | AstraZeneca AB | MedImmune Limited | Assignment of Assignor's Interest |
| Aug 23, 2018 Reel 46915, frame 874 | MedImmune, LLC | MedImmune Limited | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Nov 2030
Term ends Nov 24, 2030. Maintenance fees still fall due before then
Note
The 125 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 8,779,108.
Citations
5
later US patents cite this one
That is above the median of utility patents granted in 2019 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.